KOSDAQBiotech & Pharma287840

IntoCell

₩18,160▼ 0.87%2026-10-02 close

Market Cap

₩271.1B

Turnover

₩400M

Volume

20,000 shares

Shares out.

15M

PER

—

PBR

13.2×

EPS

-₩618

Dividend Yield

0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close

Report overview

Intocell: Clinical Data Is the Next Test

Having proven its platform business model through its first definitive license agreement with Samsung Bioepis, Intocell now faces the task of validating its next stage through clinical data from its own pipeline and additional licensing deals.

1
The 2023 research collaboration agreement (RCA) with Samsung Bioepis progressed to a first commercial license agreement (CLA) in July 2026, demonstrating the staged deal structure.
2
The company has posted double-digit billion-won net losses for three straight years from 2023 to 2025, with revenue swinging widely by quarter depending on license recognition timing.
3
Capital raised through the 2025 KOSDAQ listing boosted total equity and lowered the debt ratio, improving the balance sheet structure.
4
The lead in-house pipeline 'ITC-6146RO' is in the dose-escalation stage of a domestic Phase 1a trial, with the company expecting interim data around year-end.
5
The prior-art patent risk exposed by the 2025 termination of the ABL Bio deal remains a structural variable that could recur as the company expands into new molecules.

Business structure

Intocell is an antibody-drug conjugate (ADC) platform company founded in 2015 by Tae-kyo Park, a co-founder of LegoChem Biosciences, and listed on KOSDAQ in May 2025 under the technology special listing track.

The company's core assets are the linker platform 'OHPAS,' which connects antibodies and drugs, and the payload technology 'PMT,' designed to minimize toxicity to normal cells; based on these, it operates a business model of out-licensing the platform to partners or developing its own ADC pipeline for license-out.

Revenue mostly consists of upfront and milestone payments from technology transfer agreements, so unlike pharmaceutical companies with commercial sales, revenue swings significantly by quarter depending on when deals are signed and recognized.

Its largest partnership success is with Samsung Bioepis, with which it signed a research collaboration and option agreement (RCA) in December 2023 covering up to five ADC targets.

Samsung Bioepis exercised its option on the first target, the Nectin-4-directed candidate 'SBE303,' leading to a commercial license agreement (CLA) in July 2026, a deal estimated at a minimum of about KRW 41.8 billion including milestones based on both companies' disclosures.

In contrast, a 2024 ADC platform licensing deal with ABL Bio was terminated in 2025 after a prior-art patent issue emerged, with the counterparty notifying cancellation.

The company also has research MOUs with India's Piramal Pharma Solutions and an overseas CDMO firm, Excelron Biologics, both cited as candidates for follow-on deals.

The company describes its strategic aspiration as following the path of LegoChem Biosciences, which licenses out both platform and pipeline, and ultimately Seagen, which developed its own drugs before being acquired by Pfizer.

Earnings trend

Quarterly revenue · Operating profit

₩39,402,451-₩3.7B25Q2₩1.4B-₩1.3B25Q3₩700M-₩1.9B25Q4₩300M-₩3.5B26Q1₩800M-₩2.2B26Q2

RevenueOperating profit

Annual revenue · Operating profit

₩1.6B-₩17.4B2023₩2.9B-₩9.8B2024₩2.3B-₩10.3B2025

RevenueOperating profit

Quarterly results · Last 5 quarters
Quarter	Revenue	Operating profit	Op. margin
2025Q2	₩39,402,451	-₩3.7B	−9447.2%
2025Q3	₩1.4B	-₩1.3B	−91.3%
2025Q4	₩700M	-₩1.9B	−256.8%
2026Q1	₩300M	-₩3.5B	−1255.8%
2026Q2	₩800M	-₩2.2B	−290.2%

Annual results
Year	Revenue	Operating profit	Net income (parent)	Op. margin	ROE	Debt-to-equity
2023	₩1.6B	-₩17.4B	-₩16.8B	−1075.8%	−126.8%	96.1%
2024	₩2.9B	-₩9.8B	-₩9.9B	−337.0%	−131.8%	215.2%
2025	₩2.3B	-₩10.3B	-₩10.6B	−448.0%	−42.8%	66.7%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-09-04

Earnings analysis

Annual revenue rose from KRW 1.616 billion in 2023 to KRW 2.905 billion in 2024, then fell back to KRW 2.299 billion in 2025, reflecting the typical early-stage biotech pattern of lumpy revenue tied to license recognition timing.

Operating loss narrowed from KRW 17.39 billion in 2023 to KRW 9.79 billion in 2024 but widened again to KRW 10.3 billion in 2025, while net loss attributable to owners posted double-digit billion-won losses for three straight years: KRW 16.775 billion in 2023, KRW 9.913 billion in 2024, and KRW 10.603 billion in 2025.

Total equity fell from KRW 13.227 billion in 2023 to KRW 7.521 billion in 2024, then rose sharply to KRW 24.749 billion in 2025, a swing attributable to proceeds from the May 2025 KOSDAQ listing.

Over the same period the debt ratio moved from 96.1% (2023) to 215.2% (2024) and down to 66.7% (2025), showing that the capital raised through listing improved balance-sheet stability.

On a quarterly basis, revenue fell to about KRW 39 million in 2025Q2, spiked to KRW 1.4225 billion in 2025Q3, then declined again to KRW 728 million in 2025Q4, KRW 281 million in 2026Q1, and KRW 760 million in 2026Q2, reaffirming volatility driven by deal recognition timing.

Operating losses ranged between roughly KRW 1.3 billion and KRW 3.7 billion per quarter, reflecting steady clinical and R&D spending regardless of revenue trends.

Net loss to owners was largest in 2026Q1 at KRW 4.01 billion, exceeding that quarter's operating loss of KRW 3.531 billion, suggesting additional non-operating factors were at play.

The sum of net losses to owners over the most recent four quarters (2025Q3–2026Q2) was KRW 9.446 billion, not meaningfully smaller than the full-year 2025 net loss of KRW 10.6 billion.

Operating cash flow was negative KRW 8.626 billion in 2025, a larger outflow than 2024's negative KRW 7.046 billion, indicating that R&D and clinical spending continues to outpace cash generation.

Industry analysis

The global ADC market is projected to grow from USD 11.1 billion in 2024 to USD 28.5 billion in 2033, an 11% annual growth rate, making it a key growth segment in oncology.

In recent years, however, Chinese biotechs have rapidly caught up in linker and payload technology, intensifying competition while simultaneously raising the bar that big pharma buyers apply when acquiring technology.

Domestically, companies such as ORUM Therapeutics, Alteogen, Canaf Therapeutics, and Carusbio operate similar ADC or biologics platform licensing business models that put them in competition with Intocell, while LegoChem Biosciences and ABL Bio are key comparators with clinical-stage ADC pipelines of their own.

Intocell is expanding its strategy beyond standalone platform licensing (OHPAS/PMT) toward licensing out its own pipeline as well, modeling itself on LegoChem Biosciences, which has followed a similar path, and ultimately on Seagen, which developed its own drugs before being acquired by Pfizer.

Industry observers note that the key question is whether the preclinical competitiveness demonstrated in new linkers and payloads translates into actual clinical data, a challenge common to Intocell and ADC platform companies broadly.

Outlook

At an August 2026 press conference, Intocell said it had secured a new payload, 'iso-Nexatecan,' an improved version of its existing Nexatecan, with external CRO in vivo animal testing showing more than four times greater tumor suppression than Enhertu at the same dose.

The company also said development of a new 'TBA linker,' capable of conjugating neutral alcohol-group drugs, was nearing completion.

It plans to expand its in-house pipeline from five to ten programs by adding five new targets within the year, with CEO Tae-kyo Park saying two have already been identified and three more are in preparation.

The lead pipeline, the B7-H3-directed ADC 'ITC-6146RO,' is undergoing a Phase 1a trial at three major domestic hospitals, and the company expects to see interim data around year-end. That Phase 1a trial is designed with seven dose cohorts, and as of August 2026 dosing had progressed through the third cohort.

The follow-on pipeline, a 5T4-directed ADC, has completed CRO selection and entered preclinical development.

Given that the first deal was reached out of up to five targets under joint research with Samsung Bioepis, observers note that the remaining up to four candidates could follow a similar option-exercise-to-license-agreement structure as development progresses.

The company maintains its goal of accumulating ten technology transfer deals by 2028, though some deals have been delayed by patent issues and counterparty circumstances, meaning the pace toward that goal will depend on future clinical and deal outcomes.

Valuation

PER

—

PBR

13.2×

ROE

-42.2%

EPS

-₩618

BPS

₩1,379

Dividend per share

₩0

Intocell continues to post operating and net losses, keeping it in a range where a conventional price-to-earnings comparison is not meaningful.

Its price-to-book ratio trades at a considerable premium to net asset value even after equity increased following the listing's capital inflow, a feature common among many platform biotechs whose revenue base remains thin.

The company currently pays no dividend, consistent with the typical policy of early-stage biotechs prioritizing capital allocation toward R&D.

While there has been business momentum, including the definitive agreement with Samsung Bioepis and clinical entry for its own pipeline, these developments have not yet translated into a stable revenue stream or a turn to profit.

Ultimately, the value the market assigns can be seen as heavily dependent on expectations for future licensing deals and the success or failure of clinical data.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-09-04

Bull factors

Risk Diversification Through Platform Expansion

The addition of the new payload 'iso-Nexatecan' and the 'TBA linker' broadens the range of applicable drugs and targets, potentially reducing the impact that a patent risk tied to any single molecule has on the overall business.

The company has laid out plans to add five new targets within the year, expanding its pipeline from five to ten programs. A wider range of linker-payload combinations could also reduce dependence on any single partner or target.

Proof of a Staged Deal Structure

The Samsung Bioepis collaboration demonstrated that the structure of moving from joint research (RCA) to option exercise to a definitive license agreement (CLA) actually works in practice. That deal is estimated to be worth at least about KRW 41.8 billion including milestones.

Observers note that as development progresses, the remaining up to four targets could follow a similar deal path.

Expansion Into In-House Drug Development

The company is moving beyond platform licensing alone to directly pursue its own pipeline development and clinical trials, aspiring to the LegoChem Biosciences/Seagen-style business model. Its lead pipeline 'ITC-6146RO' is in a domestic Phase 1a trial with interim data expected around year-end. Clinical data, once obtained, could also serve as leverage in future platform licensing negotiations.

Bear factors

Lack of Revenue Visibility

Revenue is driven by the timing of upfront and milestone payment recognition, resulting in large quarter-to-quarter swings. It jumped from about KRW 39 million in 2025Q2 to KRW 1.4225 billion in 2025Q3, then fell back to KRW 281 million in 2026Q1, showing that a stable revenue base has not yet been established. This makes forecasting future results inherently difficult.

Potential Recurrence of Prior-Art Patent Risk

In 2025, a licensing deal with ABL Bio was terminated after a prior-art patent issue emerged involving a Chinese company. The company itself has explained that, due to the 18-month patent non-disclosure period, such issues were difficult to fully verify in advance. As it continues to expand its portfolio of new payloads and linkers, a similar issue could resurface.

Intensifying Competition and Rising Big Pharma Standards

The rapid pursuit by Chinese biotechs has intensified competition in ADC linker and payload technology, a dynamic cited as also raising the bar that big pharma buyers apply when acquiring technology. Several domestic competitors hold similar platforms, making differentiation an ongoing challenge. Intensifying competition could affect future deal terms or the pace at which deals are concluded.

Risk factors

Clinical Risk

The ITC-6146RO Phase 1a trial is in its dose-escalation stage, an early phase where, as of August 2026, dosing had progressed through only the third of seven planned cohorts.

If safety and efficacy data fall short of expectations, it could disrupt follow-on licensing plans and the strategy for subsequent pipelines such as the 5T4 program. Given the early stage of the trial, outcome uncertainty remains substantial.

Funding Risk

The company has recorded double-digit billion-won net losses for three consecutive years from 2023 to 2025, with operating cash flow negative every year. Industry observers have raised concerns that a delay in new licensing deals could increase pressure on securing R&D funding. The possibility of needing additional future financing cannot be ruled out.

Intellectual Property Risk

As illustrated by the 2025 termination of the ABL Bio deal, the company itself has acknowledged the structural risk that prior-art patents on new molecules cannot always be fully verified in advance due to the 18-month patent non-disclosure period.

This is a risk common not only to Intocell but to biotechs handling novel substances generally. A similar issue could recur as the pipeline continues to expand.

What to watch next

Q4 2026 (year-end)
Check whether interim data from the domestic Phase 1a trial of the in-house pipeline ITC-6146RO is disclosed, and assess the safety and antitumor efficacy signals.
Mid-November 2026 (Q3 report expected)
Examine how 2026Q3 revenue and operating loss change versus the prior quarter, and whether any new licensing upfront payments were recognized.
During H2 2026
Watch for disclosures of additional option exercises or definitive license agreements on the remaining up to four targets under joint research with Samsung Bioepis.
By the end of 2026
Track progress toward the goal of adding five new targets this year to expand the pipeline to ten programs, and whether the three remaining targets (beyond the two already identified) are finalized.

Overall view

Intocell is an early-stage biotech that generates licensing revenue from its ADC linker and payload platform, and has posted double-digit billion-won net losses for three consecutive years even after its 2025 listing.

The Samsung Bioepis collaboration boosted confidence in the business model by proving that the path from joint research to option exercise to a definitive agreement actually functions, but the termination of the ABL Bio deal showed that prior-art patent risk can genuinely affect the business.

Revenue swings widely by quarter depending on deal recognition timing, and a stable revenue base has yet to be established.

The company is broadening its platform's applicable scope by adding new payloads and linker technology, expanding its in-house pipeline from five to ten programs, while aspiring toward the LegoChem Biosciences/Seagen-style business model.

With interim data from the domestic Phase 1a trial of its lead pipeline ITC-6146RO expected by the company around year-end, clinical progress and the outcome of additional licensing deals over the coming months are likely to be the key variables shaping the company's trajectory.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 18 more articles and sources

Report written 2026-09-05 · Data as of 2026-09-04

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.